Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 14 April, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of ERIS Lifesciences Ltd

About the Company - ERIS Lifesciences Ltd

Eris Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/2007 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24232GJ2007PLC049867 and registration number is 049867. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1215.73 Cr. and Equity Capital is Rs. 13.59 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsShivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Ahmedabad Gujarat 380054complianceofficer@erislifesciences.com
http://www.eris.co.in
Management
NamePosition Held
Mr. Amit BakshiChairperson & Managing Director
Mr. Krishnakumar VaidyanathanCOO & Executive Director
Mr. Inderjeet Singh NegiExecutive Director
Mr. Kaushal ShahExecutive Director
Mr. Rajeev DalalIndependent Director
Mr. Vasudevan SujeshIndependent Director
Ms. Kalpana UnadkatIndependent Director
Mr. Prashant GuptaIndependent Director

Eris Lifesciences Ltd. Share Price Update

Share PriceValue
Today₹844.85
Previous Day₹844.00

Basic Stock Data of ERIS Lifesciences Ltd

Last Updated: April 10, 2024, 3:42 am

Market Cap 11,623 Cr.
Current Price 854
High / Low972/578
Stock P/E30.7
Book Value 177
Dividend Yield0.85 %
ROCE16.7 %
ROE18.0 %
Face Value 1.00

Data Source: screener.in

ERIS Lifesciences Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales330310278349360332306399461423403467505
Expenses205203184223220210209269309286284297324
Operating Profit1251079512714012297129151137119170181
OPM %38%35%34%36%39%37%32%32%33%32%30%36%36%
Other Income2326758352113
Interest001111177391716
Depreciation11111115151718232930354142
Profit before tax11699851171311098510112110776112126
Tax %7%9%19%9%9%8%6%8%1%6%19%17%3%
Net Profit108906810711810180931191006194122
EPS in Rs7.936.645.037.868.717.415.916.968.857.494.816.989.07

ERIS Lifesciences Ltd Quarterly Chart

ERIS Lifesciences Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales2743935095465977508569821,0741,2121,3471,6851,861
Expenses2153074144274254805336377027818581,1461,216
Operating Profit598695118172269322345372431489539645
OPM %21%22%19%22%29%36%38%35%35%36%36%32%35%
Other Income1197325263112922910
Interest11000111232242661
Depreciation3351620232636504365117164
Profit before tax558398109154270312317331394442405430
Tax %33%30%28%18%13%9%6%8%11%10%8%8%
Net Profit37587189135247295291297355406374379
EPS in Rs2,686.554,232.735,121.456,489.459,714.1817.9521.3921.1521.8426.1629.8828.1028.41
Dividend Payout %0%0%0%0%63%0%0%0%13%21%20%26%

ERIS Lifesciences Ltd Profit & Loss Yearly Chart

ERIS Lifesciences Ltd Growth

Compounded Sales Growth
10 Years:16%
5 Years:15%
3 Years:16%
TTM:17%
Compounded Profit Growth
10 Years:20%
5 Years:5%
3 Years:8%
TTM:-4%
Stock Price CAGR
10 Years:%
5 Years:6%
3 Years:12%
1 Year:43%
Return on Equity
10 Years:27%
5 Years:23%
3 Years:22%
Last Year:18%

ERIS Lifesciences Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital000001414141414141414
Reserves481061762662995538481,1371,2831,5631,8952,1822,398
Borrowings5311013771760784877830
Other Liabilities4963949198124170175205202233337634
Total Liabilities1021722713573976921,4081,5021,5021,7852,2263,4103,875
Fixed Assets23277572712327717618758549182,5682,520
CWIP0000000342272258
Investments134784167190303365356782945203722
Other Assets65981121191361572713835446367617831,275
Total Assets1021722713573976921,4081,5021,5021,7852,2263,4103,875

ERIS Lifesciences Ltd Reserves and Borrowings Chart

ERIS Lifesciences Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 30389090131200235223271375378292
Cash from Investing Activity -19-36-83-92-44-184-590-5123-323-320-975
Cash from Financing Activity -10-3-20-84-24363-221-335-82-45688
Net Cash Flow1-15-24-88-360-30145

ERIS Lifesciences Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days191516161624283153424463
Inventory Days166214166223178195178196148145166136
Days Payable13310913814292134247200213157166129
Cash Conversion Cycle52120439710284-4028-12304470
Working Capital Days1831715923-13-1759647692
ROCE %98%64%47%53%60%34%26%25%27%25%17%

ERIS Lifesciences Ltd Financial Efficiency Indicators Chart

ERIS Lifesciences Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters54.13%52.69%52.68%52.66%52.66%52.30%52.29%52.70%52.86%52.86%54.91%54.90%
FIIs12.42%13.49%13.60%13.34%13.31%15.35%15.39%15.50%14.86%13.78%13.20%13.13%
DIIs9.67%10.05%9.94%10.37%10.50%10.66%10.69%9.95%10.02%10.73%14.52%14.55%
Public23.78%23.77%23.78%23.62%23.52%21.69%21.63%21.85%22.27%22.63%17.37%17.41%
No. of Shareholders41,47046,47749,83354,22357,06151,63948,05546,74645,93144,16942,24546,496

ERIS Lifesciences Ltd Shareholding Pattern Chart

No. of ERIS Lifesciences Ltd Shareholders

ERIS Lifesciences Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
HDFC Small Cap Fund - Regular Plan50987131.89438.23
UTI Flexi Cap Fund25730670.91221.16
Franklin India Smaller Companies Fund17109001.52147.05
Aditya Birla Sun Life Equity Hybrid 95 Fund13680301.7117.58
UTI Value Fund10291261.1988.45
HSBC Midcap Fund9625801.0382.73
HDFC Large and Mid Cap Fund - Regular Plan6750000.4958.02
UTI Mid Cap Fund5916120.5850.85
Tata ELSS Tax Saver Fund5120001.2744.01
UTI Dividend Yield Fund4500001.2638.68

ERIS Lifesciences Ltd ROCE Trend

ERIS Lifesciences Ltd EPS Trend

ERIS Lifesciences Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)28.1029.8926.1621.6121.15
Diluted EPS (Rs.)28.0729.8826.1421.5921.13
Cash EPS (Rs.)36.1234.6129.3225.5423.81
Book Value[Excl.RevalReserv]/Share (Rs.)163.30140.35116.1095.4784.99
Book Value[Incl.RevalReserv]/Share (Rs.)163.30140.35116.1095.4784.99
Revenue From Operations / Share (Rs.)123.9299.1089.2579.1071.42
PBDIT / Share (Rs.)40.2937.6032.3528.2627.39
PBIT / Share (Rs.)31.6832.8429.1924.5624.74
PBT / Share (Rs.)29.7632.5329.0524.4023.08
Net Profit / Share (Rs.)27.5129.8526.1621.8421.17
NP After MI And SOA / Share (Rs.)28.1029.8826.1621.8421.15
PBDIT Margin (%)32.5137.9336.2435.7338.34
PBIT Margin (%)25.5633.1332.7031.0534.64
PBT Margin (%)24.0132.8232.5530.8532.31
Net Profit Margin (%)22.2030.1229.3027.6029.64
NP After MI And SOA Margin (%)22.6730.1429.3027.6029.60
Return on Networth / Equity (%)17.4021.2822.5222.8725.27
Return on Capital Employeed (%)13.3621.5323.7624.0327.26
Return On Assets (%)10.4217.8719.3519.1018.71
Long Term Debt / Equity (X)0.290.020.000.000.00
Total Debt / Equity (X)0.370.020.000.000.00
Asset Turnover Ratio (%)0.520.610.670.670.61
Current Ratio (X)1.733.142.802.911.90
Quick Ratio (X)1.432.552.232.491.63
Inventory Turnover Ratio (X)1.261.311.481.040.83
Dividend Payout Ratio (NP) (%)26.1520.1021.0213.140.00
Dividend Payout Ratio (CP) (%)20.0117.3418.7511.230.00
Earning Retention Ratio (%)73.8579.9078.9886.860.00
Cash Earning Retention Ratio (%)79.9982.6681.2588.770.00
Interest Coverage Ratio (X)20.94123.26243.78177.5116.45
Interest Coverage Ratio (Post Tax) (X)15.3098.87198.08138.1413.72
Enterprise Value (Cr.)8575.569359.518168.964936.178868.07
EV / Net Operating Revenue (X)5.096.956.744.609.03
EV / EBITDA (X)15.6518.3118.6012.8623.55
MarketCap / Net Operating Revenue (X)4.626.956.774.669.02
Retention Ratios (%)73.8479.8978.9786.850.00
Price / BV (X)3.544.915.213.867.70
Price / Net Operating Revenue (X)4.626.956.774.669.02
EarningsYield0.040.040.040.050.03

ERIS Lifesciences Ltd Profitability Ratios (%)

ERIS Lifesciences Ltd Liquidity Ratios

ERIS Lifesciences Ltd Liquidity Ratios (%)

ERIS Lifesciences Ltd Interest Coverage Ratios (%)

ERIS Lifesciences Ltd Valuation Ratios

Fair Value of ERIS Lifesciences Ltd Stock

Fair Value: 986.42

The stock is undervalued by 15.51% compared to the current price ₹854

Calculation basis:

  • Fair value = (P/E Ratio * (Return on Equity / 100) * Book Value) * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

*Investments are subject to market risks

Strength and Weakness of ERIS Lifesciences Ltd Stock

StrengthWeakness
  1. The stock has a high average ROCE of 39.67%, which is a positive sign.
  2. The company has higher reserves (981.08 cr) compared to borrowings (181.69 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (377.85 cr) and profit (261.54 cr) over the years.
  1. The stock has a high average Working Capital Days of 30.33, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 51.50, which may not be favorable.

FAQ

What is the latest fair value of ERIS Lifesciences Ltd?

The latest fair value of ERIS Lifesciences Ltd is 986.42.

What is the Market Cap of ERIS Lifesciences Ltd?

The Market Cap of ERIS Lifesciences Ltd is 11,623 Cr..

What is the current Stock Price of ERIS Lifesciences Ltd as on 13 April 2024?

The current stock price of ERIS Lifesciences Ltd as on 13 April 2024 is 854.

What is the High / Low of ERIS Lifesciences Ltd stocks in FY 2024?

In FY 2024, the High / Low of ERIS Lifesciences Ltd stocks is ₹972/578.

What is the Stock P/E of ERIS Lifesciences Ltd?

The Stock P/E of ERIS Lifesciences Ltd is 30.7.

What is the Book Value of ERIS Lifesciences Ltd?

The Book Value of ERIS Lifesciences Ltd is 177.

What is the Dividend Yield of ERIS Lifesciences Ltd?

The Dividend Yield of ERIS Lifesciences Ltd is 0.85 %.

What is the ROCE of ERIS Lifesciences Ltd?

The ROCE of ERIS Lifesciences Ltd is 16.7 %.

What is the ROE of ERIS Lifesciences Ltd?

The ROE of ERIS Lifesciences Ltd is 18.0 %.

What is the Face Value of ERIS Lifesciences Ltd?

The Face Value of ERIS Lifesciences Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in ERIS Lifesciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE